Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis

Arthritis and Rheumatism

Volumn 52, Issue 4, 2005, Pages 1081-1090

  Charni, Nadine ^a   Juillet, Fabrice ^a   Garnero, Patrick ^a,b  

^a Synarc   (France)

^b Synarc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 2; CTX 2; HELIX 2; PEPTIDE; TELOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALPHA HELIX; ARTICLE; CARTILAGE DEGENERATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; JOINT DESTRUCTION; KNEE OSTEOARTHRITIS; MALE; OSTEOARTHRITIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RHEUMATOID ARTHRITIS; SCORING SYSTEM; URINE LEVEL;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COLLAGEN; COLLAGEN TYPE I; COLLAGEN TYPE II; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDES; REPRODUCIBILITY OF RESULTS;

EID: 17244369359     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20930     Document Type: Article

References (40)

1. Peterfy CG. Imaging of the disease process. Curr Opin Rheumatol 2002;14:590-6.
2. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases [review]. Arthritis Rheum 2000;43:953-68.
3. Poole AR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 2003;29:803-18.
4. Heinegard D, Bayliss M, Lorenzo P. Biochemistry and metabolism of normal and osteoarthritic cartilage. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford: Oxford University Press; 1998. p. 75-84.
5. Mow VC, Setton LA. Mechanical properties of normal and osteoarthritic cartilage. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford: Oxford University Press; 1998. p. 108-22.
6. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR. Damage to type II collagen in ageing and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into cartilage with progressive degeneration. J Clin Invest 1995;96:2859-69.
7. Kojima T, Mwale F, Yasuda T, Girard C, Poole AR, Laverty S. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001;44:120-7.
8. Matyas JR, Atley L, Ionescu M, Eyre DR, Poole AR. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum 2004;50:543-52.
9. Garnero P, Delmas PD. Biomarkers in osteoarthritis. Curr Opin Rheumatol 2003;15:641-6.
10. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
11. Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, et al. Increased damage of type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994;93:1722-32.
12. Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, et al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 2001;247:25-34.
13. Croucher LJ, Hollander AP. Differential detection of type II collagen N-terminal and C-terminal denaturation epitopes in degrading cartilage. Mol Pathol 1999;52:323-31.
14. Lohmander LS, Atley LM, Pietka TA, Eyre DR. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003;48:3130-9.
15. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15.
16. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24.
17. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
18. Garnero P, Geusens P, Landewe R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S54-8.
19. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
20. Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow edema on magnetic resonance imaging is associated with type II collagen degradation in knee osteoarthritis: a 3 month longitudinal study [abstract]. Arthritis Rheum 2004;50 Suppl 9:S658.
21. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-501.
22. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
23. Buckland-Wright CB. Protocols for precise radio-anatomical positioning of the tibiofemoral and patellofemoral compartments of the knee. Osteoarthritis Cartilage 1995;3 Suppl A:71-80.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
26. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:21-30.
27. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scores. J Rheumatol 1982;9:789-93.
28. Sharp JT, Lidsky MD, Collins LS, Moreland J. Methods of scoring the progression of radiological changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
29. Van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective study of 147 patients. Br J Rheumatol 1992;31:519-25.
30. Hervey GR. Determination of creatinine by the Jaffe reaction. Nature 1953;171:1125.
31. Chan WC, White PA. Fmoc solid phase peptide synthesis: a practical approach. Oxford: Oxford University Press; 2000.
32. Harlow E, Lane D. Antibodies: a laboratory manual. Cold Spring Harbor (NY): Laboratory Press; 1988. p. 72-87.
33. Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-56.
34. Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD. Measurement of urinary excretion of nonisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 1998;41:354-60.
35. Van den Steen PE, Proost P, Grillet B, Brand DD, Kang AH, van Damme J, et al. Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J 2002;16:379-89.
36. Otterness IG, Swindell AC. Criteria for selection and application of molecular markers for clinical studies of osteoarthritis. Osteoarthritis Cartilage 2003;11:153-8.
37. Van Leeuwen MA, van der Heijde DM, Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationships of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiological damage, physical disability, joint counts and acute phase reactants. J Rheumatol 1994;21:425-9.
38. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and erosion may differ. Br J Rheumatol 1996;35:1263-8.
39. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis [review]. Arthritis Rheum 2000;43:2619-32.
40. Poole AR, Nelson F, Dahlberg L, Tchetina E, Kobayashi M, Yasuda T, et al. Proteolysis of the collagen fibril in osteoarthritis. Biochem Soc Symp 2003;70:115-23.